2 weeks Ago By ABMN Staff
Blueprint Medicines Co. ( NASDAQ:BPMC – Get Free Report ) has been assigned a consensus recommendation of “Moderate Buy” from the nineteen brokerages that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the company.
The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $120.00. Several analysts recently issued reports on the stock.
Barclays increased their price target on shares of Blueprint Medicines from $75.00 to $105.00 and gave the stock an “equal weight” rating in a research report on Monday, July 29th.
Robert W. Baird lifted their target price on Blueprint Medicines from $112.00 to $127.
00 and gave the company an “outperform” rating in a research report on Friday, August 2nd. Oppenheimer raised their price target on shares of Blueprint Medicines from $114.00 to $125.
00 and gave the company an “outperform” rating in a research note on Monday, July 8th. Morgan Stanley upped their price objective on shares of Blueprint Medicines from $110.00 to $115.
00 and gave the stock an “equal weight” rating in a research report on Friday, July 12th. Finally, Baird R W raised shares of Blueprint Medicines to a “strong-buy” rating in a research note on Friday, August 2nd. Read Our Latest Analysis on Blueprint Medicines Insider Activity at Blueprint Medicines Institutional Trading of Blueprint Medicines Several institutional investors have recently bought and sold shares of BPMC.
Gilbert & Cook Inc. increased its stake in shares of Blueprint Medicines by 8.5% in the 4th quarter.
Gilbert & Cook Inc. now owns 4,846 shares of the biotechnology company’s stock worth $447,000 after purchasing an additional 380 shares in the last quarter. Principal Financial Group Inc.
raised its holdings in shares of Blueprint Medicines by 1.7% during the 4th quarter. Principal Financial Group Inc.
now owns 14,510 shares of the biotechnology company’s stock worth $1,338,000 after acquiring an additional 247 shares in the last quarter. Axiom Investors LLC DE bought a new position in shares of Blueprint Medicines during the 4th quarter valued at approximately $2,212,000. Eagle Asset Management Inc.
grew its holdings in shares of Blueprint Medicines by 10.7% in the fourth quarter. Eagle Asset Management Inc.
now owns 231,396 shares of the biotechnology company’s stock valued at $21,344,000 after purchasing an additional 22,279 shares in the last quarter. Finally, The Manufacturers Life Insurance Company increased its position in Blueprint Medicines by 3.6% in the fourth quarter.
The Manufacturers Life Insurance Company now owns 135,969 shares of the biotechnology company’s stock worth $12,542,000 after purchasing an additional 4,746 shares during the last quarter. Blueprint Medicines Price Performance NASDAQ BPMC opened at $92.55 on Friday.
The stock has a market cap of $5.80 billion, a price-to-earnings ratio of -19.24 and a beta of 0.
58. Blueprint Medicines has a 52-week low of $43.89 and a 52-week high of $121.
90. The business has a 50 day simple moving average of $95.09 and a 200 day simple moving average of $99.
05. The company has a debt-to-equity ratio of 1.06, a quick ratio of 3.
65 and a current ratio of 3.71. Blueprint Medicines ( NASDAQ:BPMC – Get Free Report ) last released its earnings results on Thursday, August 1st.
The biotechnology company reported ($0.80) earnings per share for the quarter, beating the consensus estimate of ($1.29) by $0.
49. Blueprint Medicines had a negative net margin of 56.64% and a negative return on equity of 157.
30%. The business had revenue of $138.20 million during the quarter, compared to analysts’ expectations of $104.
02 million. During the same period last year, the business earned ($2.19) earnings per share.
The firm’s revenue was up 139.9% on a year-over-year basis. Analysts anticipate that Blueprint Medicines will post -3.
99 earnings per share for the current fiscal year. Blueprint Medicines Company Profile ( Get Free Report Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.
Recommended Stories Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter ..
